Mark Frohlich's most recent trade in Rigel Pharmaceuticals was a trade of 1,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 23, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rigel Pharmaceuticals | Mark W. Frohlich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2025 | 1,500 | 1,500 | - | - | Stock Option (Right to Buy) | |
| Rigel Pharmaceuticals | Mark W. Frohlich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2025 | 1,250 | 1,250 (0%) | 0% | 0 | Common Stock | |
| Rigel Pharmaceuticals | Mark W. Frohlich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 12,000 | 12,000 | - | - | Stock Option (right to buy) |